News
Public · Published
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
Enhertu has been approved in the European Union as a standalone adjuvant treatment for adults with resected HER2 positive breast cancer who still have invasive disease after neoadjuvant taxane-based and HER2 targeted therapy.
Published:
Updated:
What happened
Enhertu has been approved in the European Union as a standalone adjuvant treatment for adults with resected HER2 positive breast cancer who still have invasive disease after neoadjuvant taxane-based and HER2 targeted therapy.
Confirmed
Global impact / market context
Approval gives Daiichi Sankyo and AstraZeneca, which jointly develop and sell Enhertu, a new patient group in Europe. The trial showed a 53% lower risk of invasive disease returning or death versus T-DM1, which means fewer relapses may support adoption and revenue.
Analyst inference
The decision follows a positive opinion from the European Medicines Agency's human medicines committee and rests on the DESTINY-Breast05 phase 3 trial, presented in 2025 and published in The New England Journal of Medicine. That evidence base may shape how doctors and payers adopt the drug.
Analyst inference
What to watch
- Watch for how European doctors and hospitals put the approval into practice for adults with residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Confirmed
- Watch whether uptake lifts Enhertu revenue for Daiichi Sankyo and AstraZeneca, since both jointly develop and commercialize the drug and share its commercial results. Analyst inference
- Watch payers and health systems in Europe, because reimbursement decisions determine whether eligible patients can actually receive the treatment after surgery. Analyst inference
Evidence
- Original source link unavailable